stockportfolio.pro
Cogent Biosciences, Inc. (COGT)
Healthcare · Biotechnology · NasdaqGS
Cogent Biosciences, Inc. revenue & earnings — last 9 fiscal years
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $8.36M | $9.73M | $22.50M | $7.87M | $0 | $0 | $0 | $0 | $0 |
| Gross profit | — | — | — | — | — | — | — | — | — |
| Net income | $-25.49M | $-34.53M | $-31.83M | $-74.81M | $-72.27M | $-140.24M | $-192.41M | $-255.86M | $-328.94M |
| Net margin | -304.9% | -354.8% | -141.5% | -950.4% | — | — | — | — | — |
Source: Cogent Biosciences, Inc. SEC filings (10-K).
Explore 9 years of Cogent Biosciences, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track COGT in your portfolio →
Cogent Biosciences, Inc. financial history by metric
About Cogent Biosciences, Inc.
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a reversible and selective fibroblast growth factor receptor 2 inhibitor in Phase 1 trial for patients with documented FGFR mutations, including advanced cholangiocarcinoma; CGT4255, a novel ErbB2 mutant program, which is focused on actionable and underserved mutations in a solid tumor systemic and CNS involved indications; and CGT6297, a Novel PI3Ka mutant-selective inhibitor. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. Cogent Biosciences, Inc. is headquartered in Waltham, Massachusetts.
Cogent Biosciences, Inc. — frequently asked questions
What is Cogent Biosciences, Inc.'s revenue?
Cogent Biosciences, Inc. (COGT) reported revenue of $0 for fiscal year 2025, according to its SEC filings.
Is Cogent Biosciences, Inc. profitable?
No — COGT reported a net loss of $-328.94M in fiscal 2025.
What is COGT's P/E ratio?
Cogent Biosciences, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How much debt does Cogent Biosciences, Inc. have?
As of fiscal year 2025, COGT carried roughly $222.90M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Cogent Biosciences, Inc.'s market cap?
Cogent Biosciences, Inc. (COGT) has a market capitalization of about $5.52B, based on the latest data in our nightly-refreshed cache.
When does Cogent Biosciences, Inc.'s fiscal year end?
COGT's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Cogent Biosciences, Inc.'s official SEC filings (10-K and 10-Q), covering 9 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.